NCT02871882 is a Phase 2 clinical trial of Gastric Emptying test in Type 2 Diabetes Mellitus, sponsored by Mayo Clinic.

Who is sponsoring NCT02871882?

NCT02871882 is sponsored by Mayo Clinic.

What drugs are being tested in NCT02871882?

Interventions in NCT02871882: Gastric Emptying test, Mixed Oral Glucose Tolerance test, Conjugated bile acids sodium, Placebo.

What condition does NCT02871882 study?

NCT02871882 studies Type 2 Diabetes Mellitus, Obese, Overweight.

Is NCT02871882 still recruiting?

NCT02871882 is currently completed. Last updated 31 May 2023.

Are results published for NCT02871882?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-05-31 · How we verify

NCT02871882

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus

Completed Phase 2 Results posted Last updated 31 May 2023

What this trial tests

Phase 2 trial testing Gastric Emptying test in Type 2 Diabetes Mellitus in 24 participants. Completed in 30 October 2017.

Timeline

15 September 2016

Primary endpoint
18 October 2017

30 October 2017

Quick facts

Lead sponsor	Mayo Clinic
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	24
Start date	15 September 2016
Primary completion	18 October 2017
Estimated completion	30 October 2017
Sites	1 location across United States

Drugs / interventions tested

Gastric Emptying test
Mixed Oral Glucose Tolerance test
Conjugated bile acids sodium — full drug profile →
Placebo

Conditions studied

Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →
Obese — all drugs for Obese →
Overweight — all drugs for Overweight →

Sponsor

Mayo Clinic

Who can join

Adults 18 to 70, any sex, with Type 2 Diabetes Mellitus or Obese. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change in Postprandial Glucose Primary · baseline to 1 month

Measurement of the glucose concentration in the bloodstream 6 hours after eating a meal

Group	Value	95% CI
Ox Bile Extract	-2803	-5724 – 1098
Placebo	629	-4779 – 3814

Sponsor's own description

To study the effect of an ileocolonic formulation of ox bile extract on insulin sensitivity, postprandial glycemia and incretin levels, gastric emptying, body weight and fasting serum FGF-19 (fibroblast growth factor) levels in overweight or obese type 2 diabetic subjects on therapy with DPP4 (dipeptidyl peptidase-4) inhibitors (e.g. sitagliptin) alone or in combination with metformin.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets.
Fleishman JS, Kumar S. · · 2024 · cited 267× · PMID 38664391 · DOI 10.1038/s41392-024-01811-6
Ileo-colonic delivery of conjugated bile acids improves glucose homeostasis via colonic GLP-1-producing enteroendocrine cells in human obesity and diabetes.
Calderon G, McRae A, Rievaj J, Davis J, et al · · 2020 · cited 68× · PMID 32344198 · DOI 10.1016/j.ebiom.2020.102759

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02871882 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 31 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02871882.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing